C2i Genomics Gets CE Mark for C2inform Minimal Residual Disease Cancer Test

New York, N.Y.-based C2i Genomics has earned a CE-IVD mark and UK authorization for its C2inform test for minimal residual disease in cancer.

The C2inform test works by applying whole-genome sequencing and artificial intelligence to a 3-4 mL blood sample for rapid detection of cancer, monitoring of disease progression and evaluation of therapeutic efficacy. The software runs on the company’s C2intelligence cloud-based platform.

The company has recently finished several clinical trials of the diagnostic test in Europe, the U.S., Singapore and elsewhere, and plans to present the data at the 2022 American Association for Cancer Research annual meeting in New Orleans, April 8-13.